Adsorption therapy in critically ill with septic shock and acute kidney injury: a retrospective and prospective cohort study.
Acute kidney injury
Cytosorb
Haemoadsorption
Mortality
Outcome
Sepsis
Septic shock
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
18 Nov 2020
18 Nov 2020
Historique:
received:
06
07
2020
accepted:
07
11
2020
entrez:
18
11
2020
pubmed:
19
11
2020
medline:
19
11
2020
Statut:
epublish
Résumé
Haemoadsorption has been described as an effective way to control increased pro- and anti-inflammatory mediators ("cytokine storm") in septic shock patients. No prospective or randomised clinical study has yet confirmed these results. However, no study has yet prospectively specifically investigated patients in severe septic shock with sepsis-associated acute kidney injury (SA-AKI). Therefore, we aimed to examine whether haemoadsorption could influence intensive care unit (ICU) and hospital mortality in these patients. Furthermore, we examined the influence of haemoadsorption on length of stay in the ICU and therapeutic support. Retrospective control group and prospective intervention group design in a tertiary hospital in central Europe (Germany). Intervention was the implementation of haemoadsorption for patients in septic shock with SA-AKI. 76 patients were included in this analysis. Severity of illness as depicted by APACHE II was higher in patients treated with haemoadsorption. Risk-adjusted ICU mortality rates (O/E ratios) did not differ significantly between the groups (0.80 vs. 0.83). We observed in patients treated with haemoadsorption a shorter LOS and shorter therapeutic support such as catecholamine dependency and duration of RRT. However, in multivariate analysis (logistic regression for mortality, competing risk for LOS), we found no significant differences between the two groups. The implementation of haemoadsorption for patients in septic shock with acute renal failure did not lead to a reduction in ICU or hospital mortality rates. Despite univariate analysis delivering some evidence for a shorter duration of ICU-related treatments in the haemoadsorption group, these results did not remain significant in multivariate analysis. Trial registration CytoSorb https://www.cytosorb-registry.org/ (registration for content acquisition is necessary).
Sections du résumé
BACKGROUND
BACKGROUND
Haemoadsorption has been described as an effective way to control increased pro- and anti-inflammatory mediators ("cytokine storm") in septic shock patients. No prospective or randomised clinical study has yet confirmed these results. However, no study has yet prospectively specifically investigated patients in severe septic shock with sepsis-associated acute kidney injury (SA-AKI). Therefore, we aimed to examine whether haemoadsorption could influence intensive care unit (ICU) and hospital mortality in these patients. Furthermore, we examined the influence of haemoadsorption on length of stay in the ICU and therapeutic support.
METHODS
METHODS
Retrospective control group and prospective intervention group design in a tertiary hospital in central Europe (Germany). Intervention was the implementation of haemoadsorption for patients in septic shock with SA-AKI. 76 patients were included in this analysis.
RESULTS
RESULTS
Severity of illness as depicted by APACHE II was higher in patients treated with haemoadsorption. Risk-adjusted ICU mortality rates (O/E ratios) did not differ significantly between the groups (0.80 vs. 0.83). We observed in patients treated with haemoadsorption a shorter LOS and shorter therapeutic support such as catecholamine dependency and duration of RRT. However, in multivariate analysis (logistic regression for mortality, competing risk for LOS), we found no significant differences between the two groups.
CONCLUSIONS
CONCLUSIONS
The implementation of haemoadsorption for patients in septic shock with acute renal failure did not lead to a reduction in ICU or hospital mortality rates. Despite univariate analysis delivering some evidence for a shorter duration of ICU-related treatments in the haemoadsorption group, these results did not remain significant in multivariate analysis. Trial registration CytoSorb
DATABASE
METHODS
https://www.cytosorb-registry.org/ (registration for content acquisition is necessary).
Identifiants
pubmed: 33206229
doi: 10.1186/s13613-020-00772-7
pii: 10.1186/s13613-020-00772-7
pmc: PMC7672170
doi:
Banques de données
ClinicalTrials.gov
['NCT02312024']
Types de publication
Journal Article
Langues
eng
Pagination
154Références
Indian J Crit Care Med. 2014 Dec;18(12):822-4
pubmed: 25538418
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
PLoS One. 2018 Jan 25;13(1):e0191676
pubmed: 29370247
Handchir Mikrochir Plast Chir. 2017 Apr;49(2):123-126
pubmed: 27931049
Intensive Care Med. 2015 Aug;41(8):1411-23
pubmed: 26162677
Intensive Care Med Exp. 2018 May 4;6(1):12
pubmed: 29728790
Rom J Anaesth Intensive Care. 2014 Oct;21(2):134-138
pubmed: 28913446
Intensive Care Med. 2013 Feb;39(2):165-228
pubmed: 23361625
Int J Artif Organs. 2015 Aug;38(8):461-4
pubmed: 26349530
J Antimicrob Chemother. 2014 Apr;69(4):1111-8
pubmed: 24292991
J Crit Care. 2019 Feb;49:172-178
pubmed: 30448517
Crit Care. 2019 Sep 18;23(1):317
pubmed: 31533846
Intensive Care Med. 2017 Mar;43(3):304-377
pubmed: 28101605
Am J Respir Crit Care Med. 2016 Feb 1;193(3):259-72
pubmed: 26414292
Artif Organs. 2019 Feb;43(2):189-194
pubmed: 30156308
Case Rep Crit Care. 2018 Apr 29;2018:5248901
pubmed: 29854478
Ann Intensive Care. 2019 May 14;9(1):56
pubmed: 31089920
Int J Artif Organs. 2019 Apr;42(4):190-193
pubmed: 30638101
Med Klin Intensivmed Notfmed. 2019 Nov;114(8):699-707
pubmed: 28871441
Int J Artif Organs. 2019 Jun;42(6):315-317
pubmed: 30614343
Curr Treatm Opt Rheumatol. 2017 Mar;3(1):33-48
pubmed: 28944163
J Intensive Care Soc. 2015 Aug;16(3):257-264
pubmed: 28979423
PLoS One. 2017 Oct 30;12(10):e0187015
pubmed: 29084247
Intensive Care Med. 2003 Jun;29(6):876-883
pubmed: 12677369
Crit Care. 2017 Mar 27;21(1):74
pubmed: 28343448
Int J Artif Organs. 2014 May;37(5):422-6
pubmed: 24811308
Crit Care. 2004 Aug;8(4):R204-12
pubmed: 15312219